C.O. Truxton Expands Recall
The company is expanding their April 2017 voluntary recall of phenobarbital tablets.
On May 8, 2017, C.O. Truxton announced it was expanding its voluntary recall of phenobarbital tablets to all products repackaged with a Truxton Incorporated label out of caution. The original recall of phenobarbital tablets, issued April 21, 2017, was due to mislabeled product. The new recall extends to amitriptyline tablets, USP 52 mg.
An overdose of amitriptyline, which is used as a tricyclic antidepressant, could lead to uneven heartbeats, extreme drowsiness, confusion, agitation, vomiting, hallucinations, hot or cold sensations, muscle stiffness, seizures (convulsions), or fainting in humans. The company has not received any reports of adverse events associated with the recalled products as of May 8, 2017.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
